Nova (OTC: NMLSF) Submits Phase II A Psilocybin Clinical Trial Application to Health Canada
Microdose Psilocybin Safety and Efficacy Clinical Study in Fragile X Syndrome Vancouver, British Columbia– November 30, 2022 –ย Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”),ย a biotechnology company and […]
